ThermoGenesis launches new cell processing products

By The Science Advisory Board staff writers

June 23, 2020 -- ThermoGenesis has started distribution of the X-Series cell processing platform under the Corning Life Sciences brand, as part of an exclusive global distribution agreement.

The X-Series systems provide fast, sterile, automated, and efficient processing of human blood and blood products to obtain purified populations of immune cells for use in gene and cell therapy applications. The density gradient media-free and buoyancy-activated cell sorting (X-BACS) technology, which uses a novel microbubble approach without magnetic beads, was designed to support the increased demand for chimeric antigen receptor (CAR)-T cell therapies for personalized immunotherapies to treat blood cancers.

The platform includes several products such as X-Lab for automation and harvest of mononuclear immune cells and X-Wash for high-throughput cell processing. Additionally, the X-Mini selection kit uses the X-BACS technology for cell sorting.

ThermoGenesis to develop COVID-19 therapeutics
ThermoGenesis has announced that its joint venture, ImmuneCyte Life Sciences, has acquired intellectual property for developing antibody therapeutics...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter